PR Newswire BiotechOriginal article
Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II
RegulatoryBlue Light Cystoscopy SystemsPositive
AI Analysis
Summary
Photocure announced that the FDA has published a proposed order to reclassify Blue Light Cystoscopy Systems from Class III to Class II, which would lower regulatory burden for the device in bladder cancer applications.
Outcome Details
FDA published proposed order to initiate reclassification of cystoscopic systems from Class III to Class II
Importance:7/10
Sentiment:
0.70
FDAregulatoryreclassificationmedical devicesbladder cancer
Related Companies
Read the original article
Published by PR Newswire Biotech on August 14, 2026 4:22 PM